MLICM
MRNA icon

Metropolitan Life Insurance Company (MetLife)’s Moderna MRNA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,378
Closed -$1.43M – 1315
2024
Q1 		$1.43M Sell
13,378
-123
-0.9% -$12.4K 0.06% 266
2023
Q4 		$1.34M Sell
13,501
-198
-1% -$16.7K 0.06% 272
2023
Q3 		$1.41M Sell
13,699
-588
-4% -$65.6K 0.07% 237
2023
Q2 		$1.74M Sell
14,287
-490
-3% -$65.4K 0.08% 208
2023
Q1 		$2.27M Sell
14,777
-3,557
-19% -$587K 0.12% 154
2022
Q4 		$3.29M Sell
18,334
-984
-5% -$161K 0.15% 139
2022
Q3 		$2.28M Sell
19,318
-796
-4% -$121K 0.11% 181
2022
Q2 		$2.87M Sell
20,114
-914
-4% -$131K 0.13% 156
2022
Q1 		$3.62M Sell
21,028
-34,053
-62% -$5.73M 0.13% 152
2021
Q4 		$14M Sell
55,081
-1,503
-3% -$439K 0.19% 90
2021
Q3 		$21.8M Buy
56,584
+33,128
+141% +$12.2M 0.32% 56
2021
Q2 		$5.51M Buy
23,456
+2,695
+13% +$482K 0.08% 197
2021
Q1 		$2.72M Sell
20,761
-934
-4% -$135K 0.04% 384
2020
Q4 		$2.27M Sell
21,695
-423
-2% -$42.8K 0.03% 428
2020
Q3 		$1.56M Buy
22,118
+770
+4% +$53.7K 0.03% 511
2020
Q2 		$1.37M Buy
21,348
+6,710
+46% +$367K 0.02% 561
2020
Q1 		$438K Buy
14,638
+659
+5% +$15.2K 0.01% 1122
2019
Q4 		$273K Sell
13,979
-67
-0.5% -$1.19K ﹤0.01% 1707
2019
Q3 		$224K Buy
14,046
+12,233
+675% +$181K ﹤0.01% 1801
2019
Q2 		$26.5K Sell
1,813
-40
-2% -$859 ﹤0.01% 2573
2019
Q1 		$37.7K Buy
+1,853
New +$34.4K ﹤0.01% 2517

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MRNA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Moderna (MRNA) in Q2 2024, closing a stake of 13,378 shares — an estimated $1.43M sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MRNA in Q1 2019 and held it in 21 quarters. The position peaked at $21.8M in Q3 2021. 955 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 13,378 Moderna shares in Q2 2024, an estimated $1.43M.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Moderna in Q1 2019 and held it in 21 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Moderna position peaked at $21.8M in Q3 2021.
  • 955 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.